Medtronic PLC
DUS:2M6
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (25.8), the stock would be worth €81.86 (15% upside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 22.4 | €70.98 |
0%
|
| 3-Year Average | 25.8 | €81.86 |
+15%
|
| 5-Year Average | 25.8 | €81.83 |
+15%
|
| Industry Average | 27.5 | €87.26 |
+23%
|
| Country Average | 18.7 | €59.15 |
-17%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| IE |
|
Medtronic PLC
DUS:2M6
|
105.1B EUR | 22.4 | 22 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 61.9 | 56.1 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 21.7 | 25.4 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 30.5 | 36.9 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 25.3 | 23.4 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 32.6 | 43 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 42 | 41 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
38.3B EUR | 20.5 | 18.1 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 21.8 | 23.5 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 16.8 | 20.9 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
31.2B USD | 21.5 | 13.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13 |
| Median | 18.7 |
| 70th Percentile | 27.5 |
| Max | 2 454.8 |
Other Multiples
Medtronic PLC
Glance View
In the intricate world of medical technology, Medtronic PLC stands tall as one of the foremost innovators transforming the landscape of healthcare. Founded in 1949 as a humble medical supply repair shop in Minnesota, Medtronic has grown into a global titan, driven by the enduring mission to alleviate pain, restore health, and extend life. The company's breadth is vast, touching nearly every aspect of patient care, from advanced robotic-assisted surgery systems to sophisticated insulin pumps. At its core, Medtronic thrives on relentless research and development, continually bridging the gap between cutting-edge technology and practical medical solutions. By forging deep alliances with healthcare providers and systems around the globe, the company ensures its innovations are not only groundbreaking but also widely accessible. The company's financial engine purrs to life primarily through the development and sale of medical devices across four major segments: Cardiac and Vascular Group, Minimally Invasive Therapies, Restorative Therapies Group, and Diabetes Group. Each unit meticulously focuses on innovating and providing solutions relevant to its field, ensuring a diversified portfolio with robust pipelines. For instance, within the Cardiac and Vascular Group, Medtronic supplies life-saving products like pacemakers and stents while also exploring breakthrough therapies such as transcatheter heart valves. By capitalizing on a global presence, the company strategically taps into both mature markets in North America and Europe and emerging markets across Asia and Latin America, thereby driving substantial revenue streams. Through this multifaceted operational framework, Medtronic not only sustains its market dominance but also reinvests in the future of medical technology, symbolizing a perpetual cycle of growth and innovation.